TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has commenced patient dosing in Arch’s ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). St. Michael’s Hospital is the third Canadian site to successfully recruit patients in the CS-AKI Phase II trial. Along with SMH, Toronto General Hospital, part of University Health Network (Ontario) and the University ...

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary has published new data in the peer-reviewed journal Inflammation Research identifying interleukin-32 (IL-32) as a novel lipid droplet-associated cytokine that may contribute to tubular injury and inflammation in diabetic kidney disease (DKD). The newly published findings, based on human kidney tissue, show that during DKD, kidney cells accumulate lipid (fat) droplets that are coated ...

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors, effective January 15, 2026. Dr. Vink, M.D., M.B.A., has been an advisor to the pharmaceutical industry since 2015 and has served as a non-executive board member or chair of several public and private companies in North America and Europe. He has overseen or supported several transactions in these roles, including Bruker Corporation’s majority-ownership investment ...